The Swedish BioFINDER Study

The BioFINDER studies are independent and non-overlapping studies that have been initiated with the overarching aims to discover key mechanisms in Alzheimer’s disease, Parkinson’s disease and other neurodegenerative disorders. These studies are designed to develop early and accurate diagnostic tests, identify novel treatment targets and help to understand the links between different pathologies and clinical symptoms.

BioFINDER
One

The first BioFINDER study, launched in 2008, focusing on the early stages of Alzheimer’s and Parkinson’s diseases and related disorders. It includes longitudinal assessments over a period of 6-10 years.

BioFINDER
Two

The second BioFINDER study, launched in 2017, is more comprehensive than BioFINDER One. It includes a larger number of study participants and cutting-edge brain imaging such as tau-PET in all study partcipants.

BioFINDER
Sleep

The BioFINDER Sleep study targeting prodromal Parkinson’s disease was initiated in 2021. It encompasses individuals with REM-sleep behavior disorder and those in the early stages of Parkinson’s disease.

BioFINDER
Preclinical AD

The study, launched in 2022, screens a general population with a blood test to detect preclinical (pre-symptomatic) Alzheimer’s disease. Its goals are to deepen our understanding of the initial stages of the disease and to optimize future primary and secondary prevention trials.

BioFINDER
Primary Care

This BioFINDER study was launched in 2020. It includes diverse patient populations with cognitive symptoms at different primary care centers. The main aim is to improve the diagnostic and prognostic work-up in primary care of neurocognitive disorders using blood biomarkers and brief cognitive tests.

BioFINDER
Memory Clinic

This BioFINDER study, launched in 2023, is complementary to the BioFINDER Primary Care study, but targets a Memory clinic population in a secondary care setting.

News articles

  • Blood Tests: Not Just for the Impaired?

    In memory clinics and in research cohorts, immunoassays for plasma markers can now distinguish people who have Alzheimer’s disease...

    Read more...

  • Looking Good: Immunoassays for Blood Markers

    For years, scientists have been working toward blood tests for Alzheimer’s disease that could be used routinely in clinical...

    Read more...
More news...

X posts

Retweet on Twitter BioFINDER Retweeted
Emma Coomans @EmmaCoomans ·
28 Apr 1916902776279384354

So excited and honored to be invited to present the opening plenary at #AIC2025 this year in Toronto! 🧠

🙏 I would be very grateful if you could help me gather the most inspiring papers (including your own!) of the past year by completing this survey:

Reply on Twitter 1916902776279384354 Retweet on Twitter 1916902776279384354 10 Like on Twitter 1916902776279384354 28 X 1916902776279384354
Retweet on Twitter BioFINDER Retweeted
Nicholas Ashton @NicholasAshton ·
1 May 1917795053910778310

Immunoassay choice for #pTau217 is important!

In this study, we show that LMW #pTau217 is more specific to Alzheimers pathology than HMW #pTau217 immunoassay designs – which can give false-positives.



@biofinder_study @OskarHansson9

Reply on Twitter 1917795053910778310 Retweet on Twitter 1917795053910778310 9 Like on Twitter 1917795053910778310 29 X 1917795053910778310
More posts...